Eagle Pharmaceuticals, Inc. (EGRX)
USD 1.25
(4.17%)
USD 1.25
(4.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 221.67 Million USD | 71.35% |
| 2021 | 129.36 Million USD | -9.11% |
| 2020 | 142.33 Million USD | 5.44% |
| 2019 | 134.99 Million USD | -10.83% |
| 2018 | 151.39 Million USD | -15.67% |
| 2017 | 179.52 Million USD | 33.8% |
| 2016 | 134.17 Million USD | 165.27% |
| 2015 | 50.58 Million USD | 584.9% |
| 2014 | 7.38 Million USD | 17.26% |
| 2013 | 6.29 Million USD | 1104.48% |
| 2012 | -627 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | 47.78 Million USD | -2.48% |
| 2023 Q1 | 49 Million USD | 20.01% |
| 2022 Q1 | 88.11 Million USD | 193.62% |
| 2022 FY | 221.67 Million USD | 71.35% |
| 2022 Q2 | 50.47 Million USD | -42.72% |
| 2022 Q3 | 42.25 Million USD | -16.29% |
| 2022 Q4 | 40.83 Million USD | -3.35% |
| 2021 FY | 129.36 Million USD | -9.11% |
| 2021 Q3 | 31.59 Million USD | -15.45% |
| 2021 Q4 | 30.01 Million USD | -5.01% |
| 2021 Q2 | 37.36 Million USD | 22.94% |
| 2021 Q1 | 30.39 Million USD | -18.68% |
| 2020 Q3 | 37.94 Million USD | 31.73% |
| 2020 Q1 | 38.21 Million USD | 4.23% |
| 2020 Q2 | 28.8 Million USD | -24.63% |
| 2020 Q4 | 37.37 Million USD | -1.49% |
| 2020 FY | 142.33 Million USD | 5.44% |
| 2019 Q2 | 35.41 Million USD | -3.45% |
| 2019 Q4 | 36.66 Million USD | 39.82% |
| 2019 Q3 | 26.22 Million USD | -25.96% |
| 2019 FY | 134.99 Million USD | -10.83% |
| 2019 Q1 | 36.68 Million USD | -2.17% |
| 2018 Q3 | 38.34 Million USD | -5.87% |
| 2018 Q2 | 40.73 Million USD | 17.0% |
| 2018 Q1 | 34.81 Million USD | 5.26% |
| 2018 FY | 151.39 Million USD | -15.67% |
| 2018 Q4 | 37.49 Million USD | -2.21% |
| 2017 Q4 | 33.07 Million USD | -35.59% |
| 2017 Q2 | 36.28 Million USD | -38.28% |
| 2017 Q1 | 58.79 Million USD | -5.65% |
| 2017 FY | 179.52 Million USD | 33.8% |
| 2017 Q3 | 51.35 Million USD | 41.52% |
| 2016 Q1 | 15 Million USD | -3.73% |
| 2016 Q4 | 62.32 Million USD | 127.39% |
| 2016 Q3 | 27.4 Million USD | -6.92% |
| 2016 Q2 | 29.44 Million USD | 96.27% |
| 2016 FY | 134.17 Million USD | 165.27% |
| 2015 Q4 | 15.58 Million USD | 685.83% |
| 2015 FY | 50.58 Million USD | 584.9% |
| 2015 Q3 | 1.98 Million USD | -25.28% |
| 2015 Q2 | 2.65 Million USD | -91.26% |
| 2015 Q1 | 30.36 Million USD | 2632.76% |
| 2014 Q3 | 637 Thousand USD | -84.96% |
| 2014 FY | 7.38 Million USD | 17.26% |
| 2014 Q4 | 1.11 Million USD | 74.41% |
| 2014 Q2 | 4.23 Million USD | 157.48% |
| 2014 Q1 | 1.64 Million USD | 89.68% |
| 2013 Q2 | 2.14 Million USD | 84.12% |
| 2013 Q1 | 1.16 Million USD | -8.19% |
| 2013 Q3 | 1.7 Million USD | -20.53% |
| 2013 FY | 6.29 Million USD | 1104.48% |
| 2013 Q4 | 867.37 Thousand USD | -49.23% |
| 2012 Q3 | 464.42 Thousand USD | 0.0% |
| 2012 Q4 | 1.27 Million USD | 173.87% |
| 2012 FY | -627 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 32.037% |
| Embecta Corp. | 749.9 Million USD | 70.44% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 27.392% |
| Dynavax Technologies Corporation | 182.11 Million USD | -21.721% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -203.385% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 54.789% |
| PainReform Ltd. | -15 Thousand USD | 1477926.667% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -645.073% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -2558.226% |
| SCYNEXIS, Inc. | 124.51 Million USD | -78.027% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -39915.452% |
| Cosmos Health Inc. | 4.34 Million USD | -4996.459% |
| Journey Medical Corporation | 52.52 Million USD | -322.067% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -2558.226% |
| Safety Shot Inc | -74.45 Thousand USD | 297820.832% |
| Alpha Teknova, Inc. | 10.29 Million USD | -2053.011% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 48.523% |
| Bright Green Corporation | -237.01 Thousand USD | 93627.019% |
| Procaps Group, S.A. | 239.56 Million USD | 7.47% |
| Theratechnologies Inc. | 62.12 Million USD | -256.796% |
| Harrow Health, Inc. | 90.55 Million USD | -144.8% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -4571.739% |
| Biofrontera Inc. | 16.62 Million USD | -1233.217% |
| DURECT Corporation | 6.83 Million USD | -3145.118% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 57.675% |
| Cronos Group Inc. | 6.99 Million USD | -3070.895% |
| OptiNose, Inc. | 62.35 Million USD | -255.509% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 49.752% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 73259.736% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -7158.07% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 28.444% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -4009.246% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -561.992% |
| Radius Health, Inc. | 307.71 Million USD | 27.96% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -2099.609% |
| ProPhase Labs, Inc. | 16.23 Million USD | -1265.072% |
| Phibro Animal Health Corporation | 312.48 Million USD | 29.061% |
| Procaps Group S.A. | 239.56 Million USD | 7.47% |
| Alvotech | -69.42 Million USD | 419.314% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -16925.653% |
| Viatris Inc. | 6.43 Billion USD | 96.557% |
| Rockwell Medical, Inc. | 8.7 Million USD | -2446.806% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -306.1% |
| SIGA Technologies, Inc. | 122.09 Million USD | -81.563% |
| Tilray Brands, Inc. | 223.35 Million USD | 0.751% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -429.687% |
| Shineco, Inc. | 882.16 Thousand USD | -25028.32% |
| PetIQ, Inc. | 252.74 Million USD | 12.292% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 29831.433% |
| Incannex Healthcare Limited | 12 Thousand USD | -1847183.333% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 88.001% |
| Alimera Sciences, Inc. | 61.17 Million USD | -262.39% |
| Silver Spike Investment Corp. | 8.1 Million USD | -2635.838% |
| Assertio Holdings, Inc. | 125.04 Million USD | -77.27% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 3254746.895% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -5189.075% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -3281.239% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 9297.42% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -717.472% |
| Hempacco Co., Inc. | -1.21 Million USD | 18332.274% |
| Talphera, Inc. | -4.89 Million USD | 4628.58% |
| Alvotech | -69.42 Million USD | 419.314% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 68.758% |
| Currenc Group, Inc. | 17.35 Million USD | -1177.196% |
| Kamada Ltd. | 52.59 Million USD | -321.492% |
| Indivior PLC | 907 Million USD | 75.56% |
| Evoke Pharma, Inc. | 4.97 Million USD | -4352.402% |
| Flora Growth Corp. | 17.73 Million USD | -1149.712% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 9297.42% |
| Evolus, Inc. | 140.52 Million USD | -57.746% |
| HUTCHMED (China) Limited | 453.55 Million USD | 51.125% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 35.554% |
| Akanda Corp. | 111.44 Thousand USD | -198801.74% |